CH218519A - Process for the preparation of a double compound of calcium salicylate with 4-dimethylamino-1-phenyl-2,3-dimethyl-5-pyrazolone. - Google Patents

Process for the preparation of a double compound of calcium salicylate with 4-dimethylamino-1-phenyl-2,3-dimethyl-5-pyrazolone.

Info

Publication number
CH218519A
CH218519A CH218519DA CH218519A CH 218519 A CH218519 A CH 218519A CH 218519D A CH218519D A CH 218519DA CH 218519 A CH218519 A CH 218519A
Authority
CH
Switzerland
Prior art keywords
phenyl
dimethylamino
dimethyl
pyrazolone
calcium salicylate
Prior art date
Application number
Other languages
German (de)
Inventor
Fabriken Knoll A G Chemische
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of CH218519A publication Critical patent/CH218519A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/48Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  

  Verfahren zur Herstellung einer Doppelverbindung von     Caleiumsalicylat    mit       4-Dimethylamino-l-phenyl-2,3-dimethyl-ö-pyr        azolon.       Die     Sa!licylsäure    ist als     ausgezeichnetes     Mittel bei     Rheumatismen    fokaler Genese be  kannt. Sie hat jedoch den Nachteil, dass sie  über gefässabdichtende Wirkungen nicht     ver-          f        ügt,    und somit dem Ausbruch von Toxinen  und Bakterien in die Blutbahn kein nennens  wertes Hindernis entgegengesetzt.  



  Durch die Anwesenheit von Kalk kann  dieser Mangel bis zu einem gewissen Grade  ausgeglichen werden. Für die     Verabreichung     von neutralem     Calciumsalieylat    in flüssiger  Form bestand jedoch keine Möglichkeit, da  dieses. Salz in Wasser nur zu     2,8@%    löslich ist.  



  Es wurde nun gefunden, dass man ein       wertvolles        lösliches    Arzneimittel dadurch  herstellen     kann,    dass man neutrales     Calcium-          salieylat    auf     4-Dimethylamino-l-phenyl-2,3-          dimethyl-5-pyrazod.on,    z. B. in Gegenwart  von Lösungsmitteln oder im     Schmelzfluss,     einwirken lässt. Man erhält     hierbei    eine Ver-         bindung,    die auf 1     Moi    neutrales     Calcium-          salicylat    2 Mal     Pyrazolon    enthält.  



  Es     ist    durchaus     übeTraschend,    dass man       die        neue,        leicht          Verbindung     aus zwei     sehwerlöslichen        Bestandteilen    er  hält. So ist neutrales     Calciums-a;licylat    zu  2,8% und     4-Dimethylamino-l-phenyl,-2,8-          -dimethyl-5-pyrazolon    zu     5-%    in Wasser lös  lich, während die neue Doppelverbindung zu  etwa 70 % in Wasser löslich ist.  



  Ausser der Löslichkeit zeichnet sich die  neue Verbindung dadurch aus, dass sie nicht  nur die vorteilhaften Eigenschaften des     Cal-          ciumsaIicylats,    sondern auch die vorteilhaf  ten Eigenschaften des     4-Dimethylamino-l-          phenyl-2,3@-.dimethyl-    5     -pyrazolons    aufweist.

    Dementsprechend wirkt     die    neue Verbindung  nicht nur     antmrheumatisch,    sondern auch in  hohem Masse gefässdichtend, da sie nicht nur  Kalk,     :sondern    auch     4-Dimethylamino-l-plhe-          nyl-2,3,-dimethyl-5-pyrazolon    enthält, dem      nach Forschungen der     Eppingersehen    Schule  eine gefässdichtende Wirkung zukommt.  Gleichzeitig besitzt die neue Verbindung  eine erhöhte antiinfektiöse und     tenperatur-          senkende    Wirkung.  



  In Ausübung der Erfindung kann man  von vornherein die Mengenverhältnisse so  einstellen, dass ausschliesslich die gewünschte  Doppelverbindung erhalten wird. Man kann  aber auch eine der Komponenten im     Über-          achuss    anwenden und die zum Beispiel durch  Behandeln des Gemisches mit Wasser gebil  dete Doppelverbindung von dem     rberschuss     der einen Komponente trennen.  



  An Stelle von neutralem     Calciumsalicylat     können     Ca.lciumsalicylat    bildende Stoffe,  z. B.     Salieylsäure    und     Calciumoxyd    oder       Calciumearbonat.    verwendet  erden.  



  Die     wässrigen    Lösungen der Doppelver  bindung eignen sich sowohl zur bequemen  Dosierung per o..,     als    auch zu Injektionen.  



       Beispiel:     35,02 Teile neutrales     Calciumsa'licylat     und 46,24 Teile     4-Dimethylamino-l-phenyl-          2,3-dimethyl-5-pyrazolon    werden mit etwa  10     ein'        -Wasser    oder Alkohol     durchfeuchtet     und bei     Wasserbadtemperatur    gelöst.

   Durch       Verdampfen    des Lösungsmittels wird 4  Dimethy     lamino-1-pheny        l-2,3-dimethy        1-5-1>vr-          a.zolon-caleiumsalicylat    zunächst als zäh  flüssige, harzartige, später kristallisierende  Masse erhalten, die in Wasser zu etwa 70  löslich ist. Die Doppelverbindung kristalli  siert ohne Kristallwasser.

           Bei    Anwendung eines Überschusses von  4-     Dimethylamino-1-phenyl    - 2,3 -     dimethyl-5-          py        razolon    ergibt sich bei Aufarbeitung der  filtrierten Lösung, dass die Komponenten       Galeiumsalicylat        und        4-Dimethylamino-l-          phenyl    - 2,3-     d.imethyl    - 5 -     pyrazolon    in dem       stöchiometrischen        Verhältnis    1:2 in Lö  sung gegangen sind.



  Process for the preparation of a double compound of calcium salicylate with 4-dimethylamino-1-phenyl-2,3-dimethyl-δ-pyrazolone. Salicylic acid is known as an excellent remedy for rheumatism of focal origin. However, it has the disadvantage that it does not have a vascular sealing effect and therefore does not pose a significant obstacle to the outbreak of toxins and bacteria in the bloodstream.



  This deficiency can be compensated to a certain extent by the presence of lime. For the administration of neutral calcium salieylate in liquid form, however, there was no possibility, since this. Salt is only 2.8% soluble in water.



  It has now been found that a valuable soluble drug can be produced by adding neutral calcium salieylate to 4-dimethylamino-1-phenyl-2,3-dimethyl-5-pyrazod.one, e.g. B. in the presence of solvents or in the melt flow, can act. This gives a compound which contains 2 pyrazolone per mole of neutral calcium salicylate.



  It is quite surprising that you have the new, easy combination of two visually soluble components. Neutral calcium a; licylate is soluble to 2.8% and 4-dimethylamino-1-phenyl, -2,8- -dimethyl-5-pyrazolone to 5%, while the new double compound is about 70% is soluble in water.



  In addition to its solubility, the new compound is distinguished by the fact that it not only has the advantageous properties of calcium salicylate, but also the advantageous properties of 4-dimethylamino-1-phenyl-2,3 @ - dimethyl-5-pyrazolone .

    Accordingly, the new compound not only has an anti-rheumatic effect, but also has a high degree of vascular sealing, since it contains not only lime, but also 4-dimethylamino-1-phenyl-2,3, -dimethyl-5-pyrazolone, according to research the Eppinger school has a vascular sealing effect. At the same time, the new compound has an increased anti-infectious and temperature-lowering effect.



  When practicing the invention, the quantitative proportions can be set from the outset so that only the desired double compound is obtained. However, one can also use one of the components in excess and separate the double compound formed, for example, by treating the mixture with water, from the excess of one component.



  Instead of neutral calcium salicylate, calcium salicylate-forming substances, e.g. B. Salieylic acid and calcium oxide or calcium carbonate. used earth.



  The aqueous solutions of the double compound are suitable for convenient dosing per o .., as well as for injections.



       Example: 35.02 parts of neutral calcium sylicylate and 46.24 parts of 4-dimethylamino-1-phenyl-2,3-dimethyl-5-pyrazolone are moistened with about 10% water or alcohol and dissolved at water bath temperature.

   By evaporation of the solvent 4 Dimethy lamino-1-pheny l-2,3-dimethy 1-5-1> vr- a.zolon-caleiumsalicylat initially obtained as a viscous, resin-like, later crystallizing mass, which in water to about 70 is soluble. The double compound crystallizes without crystal water.

           If an excess of 4-dimethylamino-1-phenyl-2,3-dimethyl-5-py razolon is used, working up the filtered solution shows that the components of gallium salicylate and 4-dimethylamino-1-phenyl-2,3-d. imethyl - 5 - pyrazolone in the stoichiometric ratio 1: 2 have gone into solution.

 

Claims (1)

PATENTANSPRUCH: Verfahren zur Herstellung einer neuen, in Wasser zu etwa<B>70A</B> löslichen therapeu tisch wertvollen Doppelverbindung, die auf 1 Mol neutrales Calciumsal;icylat 2 Mol 4-Dimethylamino-1-phenyl - 2; PATENT CLAIM: Process for the preparation of a new therapeutically valuable double compound which is soluble in water to about <B> 70A </B> and which is based on 1 mol of neutral calcium salt; icylate 2 mol of 4-dimethylamino-1-phenyl - 2; 3@- ditnethyl-5- pyrazolon enthält, dadurch gekennzeichnet, dass man neutrales Caleiumsalicylat auf 4 -Dimethylamino-1- phenyl -2, 3- dimethyl -5 pyrazolon einwirken lässt. UNTERANSPRÜCHE: 1. 3 @ - diethyl-5-pyrazolone, characterized in that neutral calcium salicylate is allowed to act on 4-dimethylamino-1-phenyl -2, 3- dimethyl -5 pyrazolone. SUBCLAIMS: 1. Verfahren nach Patentanspruch, da durch gekennzeichnet, dass man das neutrale Caleiumsalicylat auf 4-Dimethylamino-l- phenyl-2,3-dimethyl,5-pyra.zolon in Gegen wart von Lösungsmitteln einwirken lässt. 2. Verfahren nach Patentanspruch, da durch gekennzeichnet, dass man das neutrale Cal,.ciumsalieylat auf 4-Dimet11ylamino-I- phenyl-2,3-dimethyl-5-pyrazolton im Schmelz fluss einwirken lässt. Process according to patent claim, characterized in that the neutral calcium salicylate is allowed to act on 4-dimethylamino-1-phenyl-2,3-dimethyl, 5-pyra.zolone in the presence of solvents. 2. The method according to claim, characterized in that the neutral Cal, .ciumsalieylat can act on 4-Dimet11ylamino-I-phenyl-2,3-dimethyl-5-pyrazolton in the melt flow.
CH218519D 1938-09-24 1940-04-01 Process for the preparation of a double compound of calcium salicylate with 4-dimethylamino-1-phenyl-2,3-dimethyl-5-pyrazolone. CH218519A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE218519X 1938-09-24

Publications (1)

Publication Number Publication Date
CH218519A true CH218519A (en) 1941-12-15

Family

ID=5831355

Family Applications (1)

Application Number Title Priority Date Filing Date
CH218519D CH218519A (en) 1938-09-24 1940-04-01 Process for the preparation of a double compound of calcium salicylate with 4-dimethylamino-1-phenyl-2,3-dimethyl-5-pyrazolone.

Country Status (1)

Country Link
CH (1) CH218519A (en)

Similar Documents

Publication Publication Date Title
CH218519A (en) Process for the preparation of a double compound of calcium salicylate with 4-dimethylamino-1-phenyl-2,3-dimethyl-5-pyrazolone.
DE712697C (en) Process for the production of stable humic acid solutions containing alkaline earth salts
DE593258C (en) Process for the preparation of salts of bile acids
DE629662C (en) Process for the production of a concentrated, durable, aqueous theophylline solution
DE398406C (en) Process for the production of aluminum formate solutions
DE690488C (en) Process for the production of concentrated aqueous caffeine solutions
DE818047C (en) Process for the preparation of concentrated neutral solutions of theophylline
DE636308C (en) Process for the production of praseodymium salts or their aqueous solutions
DE733301C (en) Process for the preparation of soluble double compounds of the pyrazolone series
DE419676C (en) Process for the production of indecomposable and injectable solutions for medicinal purposes containing calcium and silicon compounds at the same time
DE868331C (en) Process for the production of a bath additive containing humic acid
AT149825B (en) Process for the production of alkali or alkaline earth double compounds of dimethylxanthines with organic acids.
DE657129C (en) Process for the production of solutions or extracts from bacteria, pollen or other plant cells
DE519053C (en) Process for the preparation of salts of camphoric acid with scopolamine, hyoscyamine and atropine
DE944953C (en) Process for the preparation of a therapeutic agent consisting of the calcium salt of Ca-ethylene diamine tetraacetic acid
DE406211C (en) Process for the preparation of easily soluble double salts from monomethyl-, dimethyl- and trimethylxanthines
DE515851C (en) Process for the complete separation of technically pure rubidium (and cesium) salts from those of the alkalis
AT132707B (en) Process for the preparation of organic bromine derivatives.
DE556734C (en) Process for the preparation of a double salt of d-pseudococaine
DE637792C (en) Process for the production of durable solutions of complex lead salts
DE539289C (en) Process for the production of highly effective, debittered anthranyl glucoside-containing extracts from anthraquinone-containing drugs
AT142903B (en) Process for the preparation of water-soluble calcium double compounds.
AT147483B (en) Process for the preparation of compounds of methyl N-methyltetrahydronicotinate.
DE644078C (en) Process for the preparation of a salt of 4-oxy-3-acetylaminophenyl-1-arsic acid with the toxin of iso-octylhydrocupreine (vuzinotoxin)
DE404697C (en) Process for the production of lithium naphthenic acid